TIDMDXRX

RNS Number : 0886B

Diaceutics PLC

07 June 2021

7 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

PDMR Shareholding/Share Incentive Plan

Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified on 4 June 2021 that Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have purchased ordinary shares ("Shares") on behalf of Susanne Munksted (PDMR), in respect of her initial purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.

As announced on 30 April 2021, under the SIP Scheme, the Company will match this purchase with a matched share award being the grant of a single one-off option over an equivalent number of Shares purchased by the employee, over the forthcoming period to July 2022 and subsequent 12 month periods thereafter, in the proportion of 2:1 for all purchases up to and including April 2022 and 1:1 for all purchases thereafter. The options will be formally granted in the future, expected to be within July, at an exercise price of nil.

Enquiries:

 
 Diaceutics PLC 
Philip White, Chief Financial Officer                        Via Alma PR 
 
Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 
                                                                    7600 
Ben Maddison 
Stewart Wallace 
Nick Adams 
 
Alma PR                                               Tel: +44(0)20 3405 
                                                                    0205 
Caroline Forde                                   diaceutics@almapr.co.uk 
Robyn Fisher 
Kieran Breheny 
 

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
------  ------------------------------------------------------------------------------------------------- 
 a.      Name                                        Susanne Munksted 
                                                    ----------------------------------------------------- 
 2       Reason for notification 
        ------------------------------------------  ----------------------------------------------------- 
 a.      Position/Status                             Managing Director and PDMR 
        ------------------------------------------  ----------------------------------------------------- 
 b.      Initial notification/                       Initial 
          Amendment 
                                                    ----------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
 a.      Name                                        Diaceutics PLC 
        ------------------------------------------ 
 b.      LEI                                         213800VEWQBB39ZB8J81 
        ------------------------------------------  ----------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
------  ------------------------------------------------------------------------------------------------- 
 a.      Description of                              Ordinary shares of GBP 0.002 each 
          the financial 
          instrument, type                            ISIN: GB00BJQTGV64 
          of instrument 
 
          Identification 
          Code 
        ------------------------------------------  ----------------------------------------------------- 
 b.      Nature of the                               Ongoing non-discretionary purchase of Shares 
          transaction                                 to be matched by the future grant of nil 
                                                      cost options over Shares under the Global 
                                                      Share Incentive Plan ("SIP") 
        ------------------------------------------  ----------------------------------------------------- 
 c.      Price(s) and volume(s)                       Share purchase: 
        ------------------------------------------   ------------------------------------------------ 
                                                      Price(s)                 Volume(s) 
        ------------------------------------------   ----------------------- 
                                                      129.00 p                 111 
                                                     -----------------------  ----------------------- 
 
     Matching option award: 
     Option over 222 Shares (exercise price: 
     nil) to be awarded in July 2021 
  ------------------------------------------------------------------------------------------------------- 
 d.      Date of the transaction                     Share purchase: 28 May 2021 (Company informed 
                                                      4 June 2021) 
                                                      Option award: To be formally entered into 
                                                      in July 2021 
        ------------------------------------------  ----------------------------------------------------- 
 e.      Place of the transaction                    Share Purchase: AIM Market of the London 
                                                      Stock Exchange 
                                                      Future option award: Off-Market 
        ------------------------------------------  ----------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDKOBBOBKDKAK

(END) Dow Jones Newswires

June 07, 2021 13:23 ET (17:23 GMT)

Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Diaceutics.
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Diaceutics.